DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors

Trial Details

NCT ID
NCT06953089
Phase
PHASE2
Sponsor
DualityBio Inc.
Status
RECRUITING
Cancer Type
Hepatocellular Carcinoma (HCC) Liver Cancer
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • Los Angeles, California, United States|34.05223,-118.24368
  • Wheat Ridge, Colorado, United States|39.7661,-105.07721
  • Florida City, Florida, United States|25.44789,-80.47922
  • Atlanta, Georgia, United States|33.749,-84.38798

Key Eligibility Criteria

  • Adults aged ≥ 18 years or acceptable age according to local regulations at the time of voluntarily signing informed consent.
  • At least one measurable lesion as assessed by the Investigator according to RECIST v1.1 criteria.
  • Has a life expectancy of ≥ 3 months.
  • Has an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Hepatocellular Carcinoma (HCC) Liver Cancer Trials on Trialify →